Kiora Pharmaceuticals (KPRX) Stock: Buy, Sell, or Hold?
KPRX - Kiora Pharmaceuticals, Inc. Common Stock
$2.65
0.07 (2.71%)
▲
5d:
+3.92%
30d:
+0.38%
90d:
+1.92%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When KPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KPRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KPRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KPRX is currently trading at $2.65, which is considered extended relative to its 30-day fair value range of $2.53 to $2.64.
Technical Outlook: Technically, KPRX is in a uptrend. The price is approaching resistance at $2.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KPRX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+352.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KPRX is in a uptrend. The price is approaching resistance at $2.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KPRX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+352.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.53 -
$2.64
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 352.8% below Wall St target ($12.00)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.53 -
$2.64
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.47
Resistance Level
$2.67
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.88
Wall Street Target
$12.00
(+352.8%)
Share & Embed Analysis
Last updated: September 12, 2026 11:09 PM ET
Data refreshes hourly during market hours. Next update: 12:09 AM
Data refreshes hourly during market hours. Next update: 12:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
